Spinal muscular atrophy: Diagnosis, treatment and future prospects

Jornal de Pediatria

Volumn 86, Issue 4, 2010, Pages 261-270

  Baioni, Mariana T C ^a   Ambiel, Celia Regina ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Motor neuron; SMN protein; SMN1 gene; Spinal muscular atrophy; Therapy; Valproic acid

Indexed keywords

4 PHENYLBUTYRIC ACID; AMIKACIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; INDOPROFEN; PROKINETIC AGENT; PROTON PUMP INHIBITOR; QUINAZOLINE DERIVATIVE; STOMACH SECRETION INHIBITOR; SURVIVAL MOTOR NEURON PROTEIN; TOBRAMYCIN; VACCINE; VALPROIC ACID;

ALPHA NERVE FIBER; CALORIE; CLINICAL TRIAL; DATA BASE; DISEASE COURSE; ELECTROMYOGRAPHY; EPILEPSY; GASTROESOPHAGEAL REFLUX; GENE DELETION; GENETIC ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; LUNG INFECTION; MEDLINE; MOLECULAR BIOLOGY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUTATION; NONHUMAN; NUTRITION; ORTHOPEDICS; PHYSIOTHERAPY; PRENATAL DIAGNOSIS; RESPIRATORY CARE; REVIEW; SCOLIOSIS; SPINAL CORD; SPINAL MUSCULAR ATROPHY; SYSTEMATIC REVIEW;

FORECASTING; HUMANS; MUSCULAR ATROPHY, SPINAL;

EID: 77955896377     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1988     Document Type: Review

References (51)

1. Araújo AP, Ramos VG, Cabello PH. Dificuldades diagnósticas na atrofia muscular espinhal. Arq Neuropsiquiatr. 2005;63:145-9.
2. Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22:952-6. Review.
3. Russman BS. Spinal muscular atrophy: clinical classifications and disease heterogeneity. J Child Neurol. 2007;22:946-51.
4. Shanmugarajan S, Swoboda KJ, Iannaccone ST, Ries WL, Maria BL, Reddy SV. Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol. 2007;22:967-73. (Pubitemid 47308310)
5. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358-68. (Pubitemid 34112291)
6. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-13. (Pubitemid 32769385)
7. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet. 1997;61:40-50. (Pubitemid 27323322)
8. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027-49. (Pubitemid 47308318)
9. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931-6.
10. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol. 2006;13:121-31. Review. (Pubitemid 44486827)
11. Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518-23.
12. Sumner CJ. Molecular mechanisms of spinal muscular atrophy. J Child Neurol. 2007;22:979-89.
13. Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007;22:957-66. (Pubitemid 47308309)
14. Heier CR, Gogliotti RG, DiDonato CJ. SMN transcript stability: could modulation of messenger RNA degradation provide a novel therapy for spinal muscular atrophy? J Child Neurol. 2007;22:1013-8.
15. Meldrum C, Scott C, Swoboda KJ. Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspestives. J Child Neurol. 2007;22:1019-26. (Pubitemid 47308317)
16. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-65.
17. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovet DD, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647-54. (Pubitemid 37346071)
18. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10:597-609.
19. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000;9:333-9. (Pubitemid 30098725)
20. Burghes AH. When is a deletion not a deletion? When it is converted. Am J Hum Genet. 1997;61:9-15. Review.
21. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997;60:1411-22. (Pubitemid 27258073)
22. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6:1205-14. (Pubitemid 27351059)
23. McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919-31.
24. Oskoui M, Kaufmann P. Spinal muscular atrophy. Neurotherapeutics. 2008;5:499-506. Review.
25. Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. J Child Neurol. 2007;22:990-4.
26. Beattie CE, Carrel TL, Mcwhorter ML. Fishing for a mechanism: using zebrafish to understand spinal muscular atrophy. J Child Neurol. 2007;22:995-1003.
27. Kerr DA, Nery JP, Traystman RJ, Chau BN, Hardwick JM. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A. 2000;97:13312-17.
28. Diz MA, Diz MC. Hipotonia na infância. An Prod Acad Doc. 2007;1:184-9.
29. Reed UC. Doenças neuromusculares. J Pediatr (Rio J). 2002;78 Suppl 1:S89-S103.
30. ABRAME - Associação Brasileira de Amiotrofia Espinhal. Diferenças entre Atrofias e Distrofias. http://www.atrofiaespinhal.org/ oque-atrofia-distrofia.php. Access: 12/05/2008.
31. Pons R, Andreetta F, Wang CH, Vu TH, Bonilla E, DiMauro S, et al. Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol. 1996;15:153-8. (Pubitemid 26315036)
32. Mastaglia FL, Walton JN. Histological and histochemical changes in skeletal muscle from cases of chronic juvenile and early adult spinal muscular atrophy (the Kugelberg-Welander syndrome). J Neurol Sci. 1971;12:15-44.
33. Kolb SJ, Gubitz AK, Olszewski RF Jr, Ottinger E, Sumner CJ, Fischbeck KH, et al. A novel cell imunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol. 2006;6:6.
34. Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol. 2007;22:974-8.
35. Grondard C, Biondi O, Armand AS, Lécolle S, Della Gaspera BD, Pariset C, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci. 2005;25:7615-22. (Pubitemid 41170618)
36. Lunke S, El-Osta A. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J Neurochem. 2009;109:1557-69.
37. Sumner CJ. Therapeutics development for spinal muscular atrophy. NeuroRx. 2006;3:235-45. Review.
38. Rak K, Lechner BD, Schneider C, Drexl H, Sendtner M, Jablonka S. Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol Dis. 2009;36:477-87.
39. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481-9. (Pubitemid 37220412)
40. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2005;13:256-9. (Pubitemid 40220572)
41. Tsai LK, Tsai MS, Ting CH, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med. 2008;86:1243-54.
42. Tsai LK, Yang CC, Hwu WL, Li H. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007;14: e8-9. (Pubitemid 350135313)
43. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology. 2006;67:500-1.
44. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson Sl, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4:e5268.
45. Liang WC, You CY, Chang JG, Chen YC, Chang YF, Wang HY, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci. 2008;268:87-94.
46. Lunn MR, Root DE, Martino AM, Flaherty SP, Kelley BP, Coovert DD, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol. 2004;11:1489-93.
47. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet. 2005;14:1199-210.
48. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G, et al. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells. 2007;25:1931-9.
49. Nayak MS, Kim YS, Goldman M, Keirstead HS, Kerr DA. Cellular therapies in motor neuron diseases. Biochim Biophys Acta. 2006;1762:1128-38.
50. Lesbordes JC, Cifuentes-Diaz C, Miroglio A, Joshi V, Bordet T, Kahn A, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12:1233-9.
51. DiMatteo D, Callahan S, Kmiec EB. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. Exp Cell Res. 2008;314:878-86.